Live
Endpoints NewsRegeneron doubles down on CytomX after other pharmas walked awayClinical OMICsArthur Caplan: The Right to Life, Liberty, and Pursuit of HealthEndpoints NewsMineralys makes money moves before looming hypertension approvalFierceBiotechRegeneron pays $37M, adds $2B in biobucks to expand CytomX pactPharmaVoiceWhen the ISS comes down, will its drug R&D be lost in space?FierceBiotechAs Akeso takes center stage at ASCO, China biotech industry cements its coming of ageBioWorldSynnovation Therapeutics reports new PARG inhibitorsBioWorldFAPα inhibitors disclosed in Chomix Biotech patentBioWorldSichuan Kelun-Biotech prepares GSPT1-degrading PROTACsBioWorldChangchun Genescience identifies new USP30 inhibitorsBioWorldIMU’s $53M series A to advance high-definition immune profiling techFierceBiotechIMU Biosciences nabs $53M funding round to ‘decode’ the immune system
Endpoints News Mar 3, 2026

Prime Medicine reverses course to seek FDA approval of shelved therapy

Prime Medicine reverses course to seek FDA approval of shelved therapy

Original
Body unavailable. Use the original source.